Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 4
Submit an article Journal homepage
147
Views
38
CrossRef citations to date
0
Altmetric
Review

Use of suicide genes for cancer gene therapy: study of the different approaches

G Vassaux Cancer Research UK, Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK. [email protected]
&
P Martin-Duque Universidad Francisco de Vitoria, Facultad de Ciencias Biosanitarias, Universidad Francisco de Vitoria, Ctra, Pozuelo-Majadahonda, Km. 1,800. 28223, Pozuelo de Alarcon, Madrid, Spain. [email protected]
Pages 519-530 | Published online: 03 Mar 2005

Bibliography

  • REID R, MAR EC, HUANG ES, TOPAL MD: Insertion and extension of acyclic, dideoxy, and aranucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9- (1:3-dihydroxy-2-propoxymethyl) guanine triphosphate. Biol. Chem. (1988) 263:3898–3904.
  • BELTINGER C, FULDA S, KAMMERTOENS T, MEYER E, UCKERT W, DEBATIN KM: Herpes simplex virus thimidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA (1999) 96:8699–8704.
  • TOIMICIC MT, THUST R, KAINA B: Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bc1-2 decline and caspase-9 activation. Oncogene (2002) 21(14):2141–2153.
  • GOOL V, BAUDSON N, VELU T, CALBERG-BACQ CM: The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. (2000) 7(11):1456–1468.
  • BALZARINI J, BOHMAN C, WALKER RT, DE CLERQ E: Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol. Pharmacol. (1994) 45(6):1253–1258.
  • HAMEL W, ZIRKEL D, MEHDORN HM, WESTPHAL M, ISRAEL MA: (E)-5-(2-bromoviny1)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase-expressing cells. Cancer Gene Ther. (2001) 8(5):388–396.
  • MULLEN CA, KILSTRUP M. BLAESE RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA (1992) 89:33–37.
  • ZHANG SN, YUAN SZ, ZHU ZH, WEN ZF, HUANG ZQ, ZENG ZY: Apoptosis induced by 5-flucytosine in human pancreatic cancer cells genetically modified to express cytosine deaminase. Acta Pharmacol. SM. (2000) 21(4655–659.
  • MULLEN CA: Cytosine deaminase as a Gene Therapy of Cancer. Lattime EC, Gerson SL (Eds), Academic Press, New York, USA (1999):201–208.
  • HOGANSON DK, BATRA RK, of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. (1996)
  • TRINH QT, AUSTIN EA, MURRAY DM, KNICK VC, HUBER BE: Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res.
  • NISHIHARA E, NAGAYAMA Y, NARIMATSU M, ISHIHARA E, NAGAYAMA Y, NARIMATSU M: Treatment of thyroid carcinoma cells with four different suicide/prodrug combinations in vitro. Anti-Cancer Res. (1998) 18:1521–1525.
  • CORTES ML, DE FELIPE P, MARTIN V, HUGHES MA, IZQUIERDO M: Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. (1998) 5(11):1499–1507.
  • KOUSPAROU CA, EPENETOS AA, DEONARAIN MP: Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. hat. J. Cancer. (2002) 99(1):138–148.
  • MURRAY BP, ZGODA VG, CORREIA MA: Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the proteasome system in the degradation of this endoplasmic reticulum protein. Mol. Pharmacol. (2002) 61(5):1146–1153.
  • KARLE P, RENNER M, SALMONS B, GUNZBURG WH: Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. (2001) 8(3):220–230.
  • BURHAM PC, FONTAINE F: Extensive protein carbonylation precedes acrolein-mediated cell death in mouse hepatocytes. Biochem. Mol. Toxicol. (2001) 15(6):309–316.
  • KNOX RJ: A new cytotoxic, DNA interstrand crosslinking agent, 5- (aziridin-1-y1)-4-hydroxylamino-2-nitrobenzamide, is formed from 5- (aziridin-1-y1)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells. Biochem. Pharmacol. (1988) 37:4661–4669.
  • ANLEZARK GM: The bioactivation of 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB 1954)- Purification and properties of a nitroreductase enzyme from Escherichia coil. A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. (1992) 44:2289–2295.
  • GROVE JI, LOVERING AL, GUISE C: Generation of Escherichia colinitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res. (2003) 63(17):5532–5537.
  • MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
  • AGARD C, LIGEZA C, DUPAS B et al.:Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene The]: (2001) 8(2):128–136.
  • VILE RG, CASTLEDEN S, MARSHALL J, CAPLEJOHN R, UPTON C, CHONG H: Generation of an antitumor immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Thl-like profile of intratumoral cytokine expression. Int. J. Cancer. (1997) 71:267–274.
  • KURIYAMA S, KIKUKAWA M, MASUI K et al.: Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. hat. J. Cancer. (1999) 83(3):374–380.
  • KURIYAMA S, MITORO A, YAMAZAKI M et al.: Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellularcarcinoma. Scand. Gastroenterol. (1999) 34(10):1033–1041.
  • HALL SJ, SANFORD MA, ATKINSON G, CHEN SH: Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. (1998) 58:3221–3225.
  • PIERREFITE-CARLE V, BASQUE P, GAVELLI A: Cytosine deaminase/5- fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. Natl. Cancer. Inst. (1999) 91:2014–2019.
  • SHIBATA MA, HORIGUCHI T, MORIMOTO J, OTSUKI Y: Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer. Gene Med. (2003) 5(3):219–231.
  • BAI S, DU L, LIU W, WHITTLE IR, HE L: Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem. Biophys. Res. Commun. (1999) 259(2):455–459.
  • DIBLER MS, AN GAHRTON G: Suicide gene therapy: possible implications in haematopoietic disorders. J. Intern. Med. (2001) 249(4):359–367.
  • ASKLUND T, APPELSKOG IB, AMMERPOHL O et al.: Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp. Cell Res. (2003) 284(2):185–195.
  • ALEXANDER DB, GLODBERG GS: Transfer of biologically important molecules between cells through gap junction channels. Curc Med. Chem. (2003) 10(19):2045–2058.
  • SCHLEMMER HP, BECKER M, BACHERT P et al.: Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. (1999) 59(10):2363–2369.
  • FREEMAN SM, ABBOUD CN, WHATENBY KA et al.: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274–5283.
  • CORBAN-WILHEM H, HULL WE, BECKER G, BAUDER-WUST U, GREULICH D, DEBUS J: Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy. Gene The]: (2002) 9(23):1564–1575.
  • CORTES ML, GARCIA-ESCUDERO V, HUGHES M, IZQUIERDO M: Cyanide bystander effect of the linamarase/linamarin killer-suicide gene therapy system. Gene Med. (2002) 4(4):407–414.
  • JOUNAIDI Y: Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic. Curc Drug Metab. (2002) 3(6):609–622.
  • JUNKER K, KOEHL U, ZIMMERMAN S et al.: Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes. Gene Ther. (2003) 10(14):1189–1197.
  • WIERWRODT R, AMIN K, KIEFER M et al.: Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene The]: (2003) 10(5):353–364.
  • KIEVIT E, BERSHAD E, NG E et al.: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. (1999) 59:1417–1421.
  • YAMAMOTO S, YAMANO T, TANAKA M et al.: A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. (2003) 10:179–186.
  • FRIEDLOS F, DAVIES L, SCALON I et al.: Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander effect in two xenograft models. Cancer Res. (2002) 62:1724–1729.
  • UCKERT W, KAMMERTONS T, HAACK K et al.: Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. (1998) 9(6)855–865.
  • BLACKBURN RV, GALOFOR SS, CORRY PM, LEE YJ: Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. (1998) 58(7):1358–1362.
  • LEE YJ, GALOFORO SS, BATTLE P, LEE H, CORRY PM, JESSUP JM: Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene The]: (2001) 8(6):397–404.
  • ADACHI Y, TAMIYA T, ICHIKAWA T et al.: Experimental gene therapy for brain tumors using adenovirus mediated transfer of cytosine deaminase gene and uracil phosphoribotransferase gene with 5-fluorocytosine. Hum. Gene Ther. (2000) 11:77–89.
  • KAMMERTOENS T, GELBMANN W, KARLE P et al.: Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther. (2000) 7:629–636.
  • CHASE M, CHUNG RY, CHIOCCA EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. (1998) 16:444–448.
  • CLARKE L, WAXMAN DL: Oxidative metabolism of cylophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. (1989) 49:2344–2350.
  • AGHI M, CHOU TC, SUILING K, BREAKFIELD KO, CHIOCCA EA: Multimodel cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P4502B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. (1999) 59:3861–3865.
  • CHEN L, YU JL, WAXMAN DJ: Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by co-expression of the P450 reductase gene. Cancer Res. (1997) 57:4830–4837.
  • PAUL DB, READ SB, KULPRATHIPANJA NV et al.: Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes. J. Neurooncol (2003) 64(12):89–99.
  • STAEGE MS, GORELOV V, BULANKIN A et al.: Stable transgenic expression of IL-2 and HSV1-tk by single and fusion tumor cell lines bearing EWS/ FLI-1 chimeric genes. Pediatr. Hematol Oncol (2003) 20(2):119–140.
  • OKADA H, GIEZEMN-SMITS KM, TAHARA H et al.: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. (1999) 6(2):219–226.
  • BROCKSTEDT DG, DIAGANA M, ZHANG Y et al: Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2 and HSV-tk combination gene therapy. Ther. (2002) 6(5):627–636.
  • JANOUSKOVA O, SIMA P, KUNKE D: Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. Int. J. Oncol (2003) 22(3):569–577.
  • GUO SY, GU QL, ZHU ZG, HONG HQ, LIN YZ: Tk gene combined with mIL-2 and mGM-CSF genes in treat of gastric cancer. World J. Gastroenterol (2003) 9(2):233–237.
  • LECHANTEUR C, DELVENNE P, PRINEEN F et al: Combined suicide and cytokine gene therapy for peritoneal carcinomatosis. Gut (2000) 47(3):343–348.
  • XIE Y, GILBERT JD, KIM JH, FREYTAG SO: Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin. Cancer Res. (1999) 5(12):4424–4439.
  • PARADA C, HERNANDEZ-LOSA J, GUINEA J et al.: Adenovirus Ela protein enhances the cytotoxic effects of the herpes thymidine kinase-gancyclovir system. Cancer Gene The]: (2003) 10(2):152–160.
  • WILDER O, BLAESE RM, MORRIS JC: Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase 1 inhibitor topotecan. Hum. Gene The]: (1999) 10:2679–2687.
  • ZHANG Z, SHIRAKAWA T, HINATA N et al.: Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. Gene Med. (2003) 5(10):860–867.
  • KHIL MS, KIM CA, MULLEN SH, KIM SO, FREYTANG A: Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with cytosine deaminase gene. Clin. Cancer Res. (1996) 2:53–57.
  • ROGULSKI KR, KIM JH, KIM SH, FREYTANG SO: Glioma cells transduced with cytosine deaminase gene. Clin. Cancer Res. (1997) 2:53–57.
  • SMITH RR: Studies on the use of viruses in the treatment for the carcinoma of the cervix. Cancer (1956) 9:1211–1218.
  • KANAZAWA T, MIZUKAMI H, OKADA T et al.: Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther. (2003) 10:51–58.
  • CARRIO M, MAZO A, LOPEZ-IGLESIAS C, ESTIVILL X, FILLAT C: Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: Implications for gene therapy. Int. J. Cancer. (2001) 94:81–88.
  • LIU CS, KONG B, XIA HH, ELLEM KA, WEI MQ: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J. Gene Med. (2001) 3(2):145–152.
  • MATONO S, TANAKA T, SUEYOSHI S, YAMANA H, FUJITA H, SHIROUZU K: Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer. Int. Oncol (2003) 23 (5):1309–1315.
  • RAMESH R, MARROGI AJ, MUNSHI A, FREMAN SM: Potentiation of the bystander effect by immunization combined with suicide gene therapy. In: Gene Therapy of Cancer. Walden P, Trefzer U, Sterry W, Farzaneh F (Eds), Plenum Press, New York, USA (1998):125–131.
  • GILLGRASS AE, ASHKAR AA, ROSNTHAL KL, KAUSHIC C: Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2.1 Virol (2003) 77 (18):9845–9851.
  • HEISE CC, WILLIAMS A, OLESCH J, KIRN DH: Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. (1999) 6:499–504.
  • LOWE SW, BODIS S, MCCLATCHEY A et al.: P53 status and the efficacy of cancer therapy in vivo. Science (1994) 266:807–810.
  • FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-prolonged approach to selectively kill cancer cells: concomitant viral, double suicide gene and radiotherapy. Hum. Gene Ther. (1998) 9:1323–1333.
  • FREYTAG SO, KHIL M, STRICKER H et al.: Phase 1 study of replication-competent adenovirus-mediated of suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. (2002) 62(17):4968–4976.
  • NANDA D, VOGELS R, HAVENGA M et al.: Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-tymidine kinase. Cancer Res. (2001) 61:8743–8750.
  • RING CJA, BLAIR ED: Viruses as vehicles and expressors of genetic material. In: Genetically Engineered Viruses: Development and Applications. Ring CJA, Blair ED (Eds), Bios Scientific Publishers, Oxford, UK (2000):1–4.
  • WILDNER O: Oncolytic viruses as therapeutic agents. Ann. Med. (2001) 33 (5):291–304.
  • OKABE S, ARAI T, YAMASHITA H, SUGIHARA K: Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. Cancer Res. Clin. Oncol (2003) 129(6):367–373.
  • UCH R, GEROLAMI R, FAIVRE J et al: Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally trarisduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther. (2003) 10(9):689–695.
  • MAEDA T, O-WANG J, MATSUBARA H et al.: A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. Cancer Gene Ther. (2001) 8(11):890–896.
  • GU DL, GONZALEZ AM, PRINTZ MA et al.: Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. (1999) 59(11):2608–2614.
  • DANCER A, JULIEN S, BOUILLOT S, POINTU H, VERNET M, HUBER P: Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice. Gene Ther. (2003) 10(14):1170–1178.
  • ZHANG M, LI S, NYATI MK et aL: Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model. Cancer Res. (2003) 63(3):658–663.
  • PATIL R, CHAVEZ JB, YEE D: Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. Breast Cancer Res. Treat. (2000) 62(2):109–115.
  • LU B, FEDEROFF HJ: Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum. Gene Ther. (1995) 6:419–428.
  • KOH GY, KIM SJ, KLUNG MG, PARK K, SOONPAA MH, FIELDS LJ: Targeted expression of transforming growth factor bl in intracardiac grafts promotes vascular endothelial cell DNA sysnthesis. Clin. Invest. (1995) 95:114–121.
  • VASSAUX G, HURST H, LEMOINE NR: Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. (1999) 6(6):1192–1197.
  • MARTIN-DUQUE P, KAFTANSIS L, VASSAUX G: Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum. Gene Ther. (2004) (In Press).
  • PRENG KW, VILE R: Vector development for cancer gene therapy. Tumor Targeting (1999) 4:3–11.
  • NAGI P, VICKERS SM, DAVYDOVA J et al.: Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement. Gasmointest. Surg. (2003) 7(3):364–371.
  • PRINTZ MA, GONZALEZ AM, CUNNINGHAM M et al.: Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum. Gene Ther. (2000) 11:191–204.
  • HEMMINKI A, DMITRIEV I, LIU B, DESMOND RA, ALEMANY R, CURIEL D: Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. (2001) 61(17):6377–6381.
  • HEMMINKI A, WANG M, HAKKARAINEN T, DESMOND RA, WAHLFORS J, CURIEL DT: Production of an EGFR targeting molecule from conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Tiler: (2003) 10(8):583–588.
  • OHTAKE Y, CHEN J, GAMOU S et al.: Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene. fpn. J. Cancer Res. (1999) 90(4):460–468.
  • ROCHLITZ CF: Gene therapy of cancer. Swiss. Med. Wk/y(2001) 131:4–9.
  • ROSENBERG SA, BLAESE RM, BENNER MK et al.: Human gene marker/ therapy clinical protocols. Hum. Gene Tiler: (1999) 10(18):3067–3123.
  • FREEMAN SM, MCCUNE C, ANGEL C, ABBOUD CN: Treatment of ovarian cancer using HSV-TK gene-modified vaccine-regulatory issues. Hum. Gene. Ther. (1992) 3:342–349.
  • YAMAMOTO S, SUZUKI S, HOSHINO A, AKIMOTO M, SHIMADA T: Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor specific cytotoxic T cells in mice. Cancer Gene Ther. (1997) 4(2):91–96.
  • RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumours by intratumoral implantation of retroviral vactor producing cells. Nat. Med. (1997) 3:1354–1361.
  • SHALEV M, KADMON D, TEH BS et al.: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J. Urol. (2000) 163:1747–1750.
  • MARKERT JM, MEDLOCK MD, RABKIN SD: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7:867–874.
  • RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7:859–866.
  • CUNNINGHAM C, NEMUNAITIS J: A Phase 1 trial of genetically modified Salmonella hphimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum. Gene Ther. (2001) 12(12):1594–1596.
  • FREYTAG SO, STRICKER H, PEGG J et al.: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high risk prostate cancer. Cancer Res. (2003) 63:7497–7506.
  • PEARSON S, JIA H, KANDACHI K: China approves first gene therapy. Nat. Biotechnol (2004) 22(1):3–4.
  • DE PALMA M, VENNERI MA, ROCA C, NALDINI L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. (2003) 9(6):789–795.
  • FERRARI N, GLOD J, LEE J, KOBILER D, FINE HA: Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther. (2003) 10(8):647–656.
  • PIEREBOEVA L, KOMAROVA S, MIKHEEVA G, KRASNYKH G, CURIEL DT: Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells (2003) 21(4):389–404.

Websites

  • www.wiley.co.uldgenetherapy/clinical/ The Journal of Gene Medicine.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.